P-037

P-037 is an investigational drug candidate currently in development by Pangea Pharmaceuticals for the treatment of pain and inflammation. Pangea Pharmaceuticals is a specialty pharmaceutical company that primarily utilizes the FDA's 505(b)(2) regulatory pathway, which allows for the approval of new formulations, dosage forms, or delivery methods of previously approved drugs. While the specific active pharmaceutical ingredient (API) and molecular target for P-037 have not been publicly disclosed, the candidate is part of a pipeline focused on optimizing existing therapeutic agents to improve clinical outcomes or patient compliance in inflammatory and painful conditions.